N
Google TrendSOCIAL SECURITY 2027 COLA ANNOUNCEMENT (500+) — When will 2027’s Social Security COLA be announced?
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:social security 2027 cola announcement500+benfica vs vitória sc200+energy ceasefire200+elliot anderson200+r.c.d. mallorca - u. d. las palmas200+quinyon mitchell2000+tornado north carolina1000+sean young500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Induction chemotherapy fo" (30 stories)

Top Headline Story

Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study
Lead StoryNaturegeneral
Jun 22

Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBLOVBrQ2tDbkc2dEcwUndyOFFrZkRjZTFXV1JMbWpTMUtJbmNWSWNhSmFfZGdJN29oSEUzUThuekRoSXNsY01uWjJhRjRhelc3Wm85ZnRfV25wTEVPN0Vr?oc=5" target="_blank">Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
500+25m ago

social security 2027 cola announcement

When will 2027’s Social Security COLA be announced?

Filter stories
200+35m ago

benfica vs vitória sc

Benfica tem 'roupa nova' para receber o V. Guimarães: o onze provável

Filter stories
200+35m ago

energy ceasefire

Trump announces partial ceasefire in Ukraine war as Zelenskyy says deal is ‘news to me’

Filter stories
200+35m ago

elliot anderson

James McAtee: How Oliver Glasner has transformed Nottingham Forest midfielder from forgotten man to his new Adam Wharton

Filter stories

Search Results for "Induction chemotherapy fo"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Azacitidine-Venetoclax Beats Induction Chemo as Upfront AML Therapy
Targeted Oncologygeneral

Azacitidine-Venetoclax Beats Induction Chemo as Upfront AML Therapy

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNSm5QMVhXZUw1emNzc3k1MVR4MDZnUUZ1RXBHeS1XdWdzb0J2RTVHSkY1U2IwWGZrbmlzRjROejctb2VQcFc5RjRDV2YwRm9oTkpaU3d2dm45WUhYNnBDS3VKdlFRTk9wV3RQdGo3OG9jRGoxbVF0em1HOW16TXJFNjBHTjZSUDBranFjRVd6VThfV3ozbnc?oc=5" target="_blank">Azacitidine-Venetoclax Beats Induction Chemo as Upfront AML Therapy</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Induction Chemotherapy in HPV-Positive Head and Neck Cancers
ASCO Daily Newsgeneral

Induction Chemotherapy in HPV-Positive Head and Neck Cancers

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxOeU9abVc5eDhxZDNZNUI2ZHR4dGhUZi1EczJkZC1jamFaV2Z5ekpIc0p4MWpXREtZNlcxUDlMVDZ3Nl9Hc3FxeVJib2NISGoxYlBwd2phdU5FNmFfQ3VTYXBMUlB4bjlYNVlKSUs0dThOVVpraDl2a29wRDdRZDkyMl9tQ1NJZnBOT1NDTi1BZ19kZXM2Y0E?oc=5" target="_blank">Induction Chemotherapy in HPV-Positive Head and Neck Cancers</a>  <font color="#6f6f6f">ASCO Daily News</font>

Read Full StoryMore like this
Tumor-preserving Deformable Registration of Longitudinal DCE Breast MRI during Neoadjuvant Chemotherapy
RSNA Journalsgeneral

Tumor-preserving Deformable Registration of Longitudinal DCE Breast MRI during Neoadjuvant Chemotherapy

<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTFBmLUgzZDVfa2l3aW40ZEl0c0NjX2VJNkwxeTFYc1RWU3dNRUFSeHNTejhSTWdVX2JnRWlxakFfQzV2Y3VycjBENDh5d2lkeXByNFhITTJVRUpDYnBkbmc?oc=5" target="_blank">Tumor-preserving Deformable Registration of Longitudinal DCE Breast MRI during Neoadjuvant Chemotherapy</a>  <font color="#6f6f6f">RSNA Journals</font>

Read Full StoryMore like this
All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia
NEJMgeneral

All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE0xaHBSUkZ5b1E2WS1wbWdxVGwtNF9aYUs5OWs3NUJsWXl6akdrTTc5aDhqYXluX3RudVNDLUQ4UlJxMWZKbW9pN3NRdW5lbG90WXA4MzJWZFRwaHFWa2hz?oc=5" target="_blank">All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia</a>  <font color="#6f6f6f">NEJM</font>

Read Full StoryMore like this
Induction chemotherapy for head and neck cancer: a changing paradigm
Via Medica Journalsgeneral

Induction chemotherapy for head and neck cancer: a changing paradigm

<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxNT0hJR3lWaDNnT0RUU0VDSWl6UThqaW1zZkt4bUFkOWttRF9yb0VWd2o0RGd3SFhDT3ctWF92TTFuRnRfUjF0VmNPd1ctdWxBVWdhWmlScEs1OWdKYVkxeTNHcHF3YzVieUlqcGd3T2xKRC1aYlJKS0ExT3d4WXlxbXVVM3A2dw?oc=5" target="_blank">Induction chemotherapy for head and neck cancer: a changing paradigm</a>  <font color="#6f6f6f">Via Medica Journals</font>

Read Full StoryMore like this
Azacitidine and venetoclax (AZA/VEN) for older adults with AML ineligible for intensive chemotherapy
Penn Medicinegeneral

Azacitidine and venetoclax (AZA/VEN) for older adults with AML ineligible for intensive chemotherapy

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxPVjNoX0JiSUtHN3ZGNkp4a1VvRTFTdXFUT0tCc0hlVGFQczlhZmt0OVVIaG9tTmoxZ1dlZVVvV0dwRGhLTmVtTHNRMTkwR0E2aGFMaTRuc2lFb2ZmVzR1X2UtX1VVT1E5ekNQVUt2VWd5UW5lbndRSlAxVzdKQ3JaclRGd2ZzdlM3QWlVN001VldRX0ZHdEN3TTlYYkw1T09MXzhCdWplRnZnS2pOTlhKMWEwQVNncW16eTBDZ0JmZ2VOTGphNzlBSDBFbVlvaEl1MU01RGZGUQ?oc=5" target="_blank">Azacitidine and venetoclax (AZA/VEN) for older adults with AML ineligible for intensive chemotherapy</a>  <font color="#6f6f6f">Penn Medicine</font>

Read Full StoryMore like this
Venetoclax combined with intensive chemotherapy as induction chemotherapy in newly diagnosed AML with FLT3-ITD-mutation
Naturegeneral

Venetoclax combined with intensive chemotherapy as induction chemotherapy in newly diagnosed AML with FLT3-ITD-mutation

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5GeU1XTU9HNHRjazhrZkJyWXZzTk92MVBOZm5JdjZDOXlDMWdTSjI3N0FnWmhRWHJCcVJLa1dLUERHdl96b21RaDlGcS1MLW1iNEJLRWt3ek9KZ05lNU9V?oc=5" target="_blank">Venetoclax combined with intensive chemotherapy as induction chemotherapy in newly diagnosed AML with FLT3-ITD-mutation</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Neoadjuvant Therapy in Nonmetastatic Colon Cancer: Evolving Treatment Paradigms
ASCO Daily Newsgeneral

Neoadjuvant Therapy in Nonmetastatic Colon Cancer: Evolving Treatment Paradigms

<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxQMlZYallFSnBnTVNEUks5R1ZiWGVnQVFYMWRMcTBxbVJkNnJfUW9CRVJwNzRheDdYaHFMeDR3NEd0cmQ4RndYNV9MZjlObWJCQjlxVkpDQ1lmdVJ1Q2sxd3pxQWwyWXNhSzdyTDZ0dnVVNWIzZkNEaFllR21YWFg5R1ZueHZkcTg?oc=5" target="_blank">Neoadjuvant Therapy in Nonmetastatic Colon Cancer: Evolving Treatment Paradigms</a>  <font color="#6f6f6f">ASCO Daily News</font>

Read Full StoryMore like this
Concurrent chemoradiotherapy plus nimotuzumab versus chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma with a suboptimal response to induction chemotherapy: a randomized phase 2 trial
Naturegeneral

Concurrent chemoradiotherapy plus nimotuzumab versus chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma with a suboptimal response to induction chemotherapy: a randomized phase 2 trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1SNXhpRUVvQTdjS2h1c3pmcWJacnVfRk9Fa1NNQllXSzJzRnI1NmhWVHBLdDVyUE1nMld5UWdpR3N0YXJIVWphbHFvemx6MVdXeDNmTTZPemswek01eTcw?oc=5" target="_blank">Concurrent chemoradiotherapy plus nimotuzumab versus chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma with a suboptimal response to induction chemotherapy: a randomized phase 2 trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Incorporating early cfEBV DNA clearance into clinical risk stratification to tailor induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma
Naturetech

Incorporating early cfEBV DNA clearance into clinical risk stratification to tailor induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFB5MkpFUnRPd01XVkdkX3gwT3hxVXRTMWlYdEVGbTFVNEFCZEVVZ2Uxak9fTk0tVzZ1WDN5ODQtMkJrSVdDSXlrZGNfblpOUmg2Qm5RUDY5YTRVQ09qOGhr?oc=5" target="_blank">Incorporating early cfEBV DNA clearance into clinical risk stratification to tailor induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo study
Naturegeneral

Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo study

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9Hb1I4X2NndElDb1R0OTR5ME80YzVHZWVSZEZDTDNBMDJzUk10SDBERkVrZVFmYTNfWVkwbVlCS0VjVXlsbnRQc2N2cndJUEtwRkk0YzBWdk9kSTkxVGpR?oc=5" target="_blank">Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo study</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Anlotinib combined with neoadjuvant chemotherapy for HR+/HER2− breast cancer (ACNTBC): a prospective, single-arm, single-center phase II clinical study with real-world validation
Natureworld

Anlotinib combined with neoadjuvant chemotherapy for HR+/HER2− breast cancer (ACNTBC): a prospective, single-arm, single-center phase II clinical study with real-world validation

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5VbXh1V2Fvb3hpZW1nUnFqaGU3VWF3eTVNTTZ4OXk2dm8tczBqZ2JXMTBUcGZxMExKekh6YjVhYWVPMFBDb2FIUGVuQWVpZC1SMGRmQlZDWVV5OVBFbGJz?oc=5" target="_blank">Anlotinib combined with neoadjuvant chemotherapy for HR+/HER2− breast cancer (ACNTBC): a prospective, single-arm, single-center phase II clinical study with real-world validation</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Total neoadjuvant chemotherapy combined with PD‑1 blockade and IL‑2 in MSS/pMMR locally advanced rectal cancer: short-term results of a prospective, single-arm phase II study
Naturegeneral

Total neoadjuvant chemotherapy combined with PD‑1 blockade and IL‑2 in MSS/pMMR locally advanced rectal cancer: short-term results of a prospective, single-arm phase II study

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1JNWFqQy1xbi1HZFVVTm5CSUVaT3ZveVUtYXNWY2lwQk9NX3JJdEVkMkpUTU1jazRXa3YzQ3hKMzNQQ3pUVUVhY0t5TWE1QVZGZDQtSk1VQTNoUktyUnVj?oc=5" target="_blank">Total neoadjuvant chemotherapy combined with PD‑1 blockade and IL‑2 in MSS/pMMR locally advanced rectal cancer: short-term results of a prospective, single-arm phase II study</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO)
Natureworld

Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO)

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBoSXJtSHRRVFJHNEtqY2c1YXBwa1RpYXRlUTQtcllEWGRzTUxjNnZrRjJweVpNbnZqWFlDVV9xSW5KWk5yM0kycmtxWTQ2Ym9VdDVtX3diZEJrdEtVSHdF?oc=5" target="_blank">Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO)</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Dynamic changes of the immune microenvironment in ovarian cancer following neoadjuvant chemotherapy
Natureworld

Dynamic changes of the immune microenvironment in ovarian cancer following neoadjuvant chemotherapy

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1qanZjU2xvRnFwaDI3TmNGLUJCZlAtLXVaUlVqRDNhZUxqTEVBQkJXS21IbWU4cnI0dTdLaWc1V254WVJUd19zMHdQM0EzaFAySzlTZ3YyTlFuaUVUT05R?oc=5" target="_blank">Dynamic changes of the immune microenvironment in ovarian cancer following neoadjuvant chemotherapy</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
A nutritional risk index-based nomogram for predicting prognosis and identifying induction chemotherapy beneficiaries in nasopharyngeal carcinoma | Scientific Reports
Naturegeneral

A nutritional risk index-based nomogram for predicting prognosis and identifying induction chemotherapy beneficiaries in nasopharyngeal carcinoma | Scientific Reports

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBTM2hMVWU3R01mai02UkxhSDB0QWg4OEFhOG5WYzNEOTlGZzVsbnJFMDlTQ1RWcm1ITm9wQXhfZWRoNVEyRTc2WDQtOE1kcmV0cTJjMWRPLTVFbUxoTlU4?oc=5" target="_blank">A nutritional risk index-based nomogram for predicting prognosis and identifying induction chemotherapy beneficiaries in nasopharyngeal carcinoma | Scientific Reports</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial
Naturetech

Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9XTVdVbGl6cFVVbWNvaFIwbnJWd2NYemVkSUV3SGI0NFcweXplS3paSDFwV3YwUXhOWW5KTG5BaFZBN1pMc3VQaWt1TVN5OFZFQkZnZ0xnWmZyWXVjVFlr?oc=5" target="_blank">Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Value of whole-body diffusion-weighted MRI for the prediction of surgical and clinical outcome after neoadjuvant chemotherapy in advanced ovarian cancer
Naturegeneral

Value of whole-body diffusion-weighted MRI for the prediction of surgical and clinical outcome after neoadjuvant chemotherapy in advanced ovarian cancer

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9nVTJmSFZveFdDMmlZcDRlY1ZQbUhPMXowSzQ4ekVzNVNMaTV2a2VJRkNIVk1idlRWWXZtS29FUVhqbnJnTUQzQjcwMThGcTc5NHZPWW5OdHVkMlVvVGZB?oc=5" target="_blank">Value of whole-body diffusion-weighted MRI for the prediction of surgical and clinical outcome after neoadjuvant chemotherapy in advanced ovarian cancer</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
The utilization of CEUS and SWE for predicting pathological complete response to neoadjuvant chemotherapy for invasive breast cancer
Naturegeneral

The utilization of CEUS and SWE for predicting pathological complete response to neoadjuvant chemotherapy for invasive breast cancer

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5CcTlvQ3FWd0ZrNE5GY2FNd1U1elMwZF9LU3Y1Y2ltWDVOWW12QjF2NkhvNjI1SWFfU2lINjQtMnlHTFgzUGhaZTI2enV4anBLLUUwcGE0VXJHTE9RWGhV?oc=5" target="_blank">The utilization of CEUS and SWE for predicting pathological complete response to neoadjuvant chemotherapy for invasive breast cancer</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia
The New England Journal of Medicinegeneral

Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9FSjQ5RWJmX09OQ0laaW5aLThHblp2NHBPQXNYSkVnOFBxb3Jja3ZwbERSOTlOSkRITllBTTVnc0JjV0hZcEFDT0hqd1pBMG0zOWFiLS1Icld6aG54eEN3?oc=5" target="_blank">Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia</a>  <font color="#6f6f6f">The New England Journal of Medicine</font>

Read Full StoryMore like this
Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma: a single-arm phase II trial
Natureworld

Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma: a single-arm phase II trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE55dmFWdzJ1eFNPdW1ZV0MzNk5RQkZrVEpoTVFqUlp0b3NyZURKY0NFZy04RVNaTkhMajNueWs3RHZVWURjR3FhSXFlcTNnOGF1R2w2S2lSN2VfREZFa1I0?oc=5" target="_blank">Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma: a single-arm phase II trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Romiplostim for Chemotherapy-Induced Thrombocytopenia
The ASCO Postgeneral

Romiplostim for Chemotherapy-Induced Thrombocytopenia

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNRUZVTHAtdzdzV1BkcWxKZ0c4MEhjNjNES3VoU2MybkFLNzhWUEszWkFralRaRE1EZHZUZndOSDFjQ0ZRY0dnbm9SQ2h1NDdraENVUU1FcEdwRmxXOVg3aHFnd0V0dE51blhEcGtCSkRXM2FFMUpTSmlhU0ZMVDdPeEdGWmVWSUpMajlnM21GWmxRbkh5WHc?oc=5" target="_blank">Romiplostim for Chemotherapy-Induced Thrombocytopenia</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
ASH 2025: Refining Chemotherapy and Biomarker-Adapted Strategies in AML
Cancer Therapy Advisorgeneral

ASH 2025: Refining Chemotherapy and Biomarker-Adapted Strategies in AML

<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxNa25TV0hJSm9TY1c0bV9MWE5fWGg4NF9iREMzV0h6bWoxb29YVjlpcGU3YUdNWkhuUHh0aThoUHFkMVc2RGZ5QW15RUlqS2VuQ0dDNnlWb01iLUJpQkJjMUtleklEMXhDeER1X29yRDFwTjVfbEI1aXZtR1A2Q0FqV0NnMWFrRllDWGc?oc=5" target="_blank">ASH 2025: Refining Chemotherapy and Biomarker-Adapted Strategies in AML</a>  <font color="#6f6f6f">Cancer Therapy Advisor</font>

Read Full StoryMore like this
Neoadjuvant chemotherapy for high-risk upper tract urothelial cancer
Sage Journalsgeneral

Neoadjuvant chemotherapy for high-risk upper tract urothelial cancer

<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTFA1SUFiVHkzRGZRTktuYUEzQ0MzNTFGbndwZDRVdEZHb0hYVW5ENldEQ2lIZEE2b2YwQU05ZnZ3RzdyeVJYLXpkME55TTVjZWRXdHZmZUFNcTdqLUhVWXVfUXdvNEV1b0Jzbnc?oc=5" target="_blank">Neoadjuvant chemotherapy for high-risk upper tract urothelial cancer</a>  <font color="#6f6f6f">Sage Journals</font>

Read Full StoryMore like this
After 5 Decades, Is Standard AML Treatment for Young and Fit Patients About to Change?
Oncology News Centralworld

After 5 Decades, Is Standard AML Treatment for Young and Fit Patients About to Change?

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNaFNDbnhJcnQ1X3RUenFVV0lJdk5uc1FxSWc3ZFkwUDM4WjE3UjFVZERFX25RWExwNm9sLXNUUWJJZldCRnAwakZyajN4MkV1RE0zZHVZbU00MFZMaTFTWS00ZVFOeHczbDIwdFBSU3Z2dEswVlV1ZVVaYkppOUU2V1NpV2JTUXlXa0lmRWwwejBORXZVWDZYZHlGNWwzSmgxNnJaaDk2bU5Pcm5CanBEUDRPQjBheHpqRGVBNDdmcl9lQQ?oc=5" target="_blank">After 5 Decades, Is Standard AML Treatment for Young and Fit Patients About to Change?</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
Doublet Therapy Yields Higher Response Rates and Fewer Complications Than Standard Induction in AML
The ASCO Postgeneral

Doublet Therapy Yields Higher Response Rates and Fewer Complications Than Standard Induction in AML

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxQejJwamMwZmQzQjZpMXd6OG9RNldFbUZ6U3lIZ0p1QUVNY1VYSWQ2dGdlSE5BeG1xUkctSDJwOGhYeFV4UmlVQ1poUnhiaEtVZzdNMUl5X0x4Y3o4SGROTHlUMkh0NHVPNFNGcVYwZUdoelE0M1BiQ3QzVGhoQXBKRjhmQzNxNk1ZeGxBMlU5ZGZ2WTZSY0VKQkVZbTNQSEZ1MTgtNXJhSG80MVhfWUJkNS1jeGJJRjgtY1hyVnZXdmFhUFhxcWE4VGdCQTlNV1JVU0p1ZGdHOA?oc=5" target="_blank">Doublet Therapy Yields Higher Response Rates and Fewer Complications Than Standard Induction in AML</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
ASH 2025 | PARADIGM: Azacitidine + venetoclax vs conventional induction chemotherapy in fit adults with ND AML
aml-hub.comgeneral

ASH 2025 | PARADIGM: Azacitidine + venetoclax vs conventional induction chemotherapy in fit adults with ND AML

<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxPdW0zUThabm84c09NWE1PVnBwT3JzQ1E1NFhjSzJPQk5iMXhkXzV6M0t3Zmp5cm5oUjNxZ0xjLU5ocVhWWUc5VG1rZmJkYTRIVXpiUVdNQ05qMHQzajVMblFmMFY0RFM4V3FuQWpUN2kwbktZWjZYQmEtLTRINkNpZ2MxaUFQR1htLTRzeXNVVFU0UkpTdmFNeGdLTEQyV0E1a0h0SFZXTUFRTEt2VXFqZE1QeVRKYnNwQWhJLVYtSTZDSU4weDNlQm9COEl2RkZoUDlsMjl4WEJpUWVVNGc?oc=5" target="_blank">ASH 2025 | PARADIGM: Azacitidine + venetoclax vs conventional induction chemotherapy in fit adults with ND AML</a>  <font color="#6f6f6f">aml-hub.com</font>

Read Full StoryMore like this
Neoadjuvant chemotherapy, DEB-TACE, and 3D-printed prosthesis for primary pelvic pleomorphic undifferentiated sarcoma: a case report
Frontiersworld

Neoadjuvant chemotherapy, DEB-TACE, and 3D-printed prosthesis for primary pelvic pleomorphic undifferentiated sarcoma: a case report

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxNTk84VGI0MVZsdGFkUGIyV2w1dmV6TXJtVlNqcXBFbmxDUHhfVDRiN1ZJbVpEM2w1d0R3RGZJOWM5Y1JMaV9LTlNWcWxlazRCWWVXQUJ2eFlRSlhXalFIdndfanJEREd6RXhXR1NrUjA4cmVIV21tSFlNZy10Y0VabjJjbGVvT3d1Y1IwRDhB?oc=5" target="_blank">Neoadjuvant chemotherapy, DEB-TACE, and 3D-printed prosthesis for primary pelvic pleomorphic undifferentiated sarcoma: a case report</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Azacitidine/Venetoclax Combo Data Challenge Chemo in Fit Patients With AML
AJMCgeneral

Azacitidine/Venetoclax Combo Data Challenge Chemo in Fit Patients With AML

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOQjdwVldocUpLd3hZcmp2VV9MQ0gwVjlOaWFIamdFc3pDUHAzTTBfV1hGZEs2N0d5ejJVNjkzbmlBOHE2ajZLUWhVUlVFaVNhQkJBSHhlWUlaNEUtZ0pWWGZORmVnSHlEYURHUG04M3NsdXRrOGFuTHB1MnBvTS1yME5SZzN5VUNIZm9wYUhIX0ZoeTJ0Si1lUVpIWHh1c0VFOTh6bmFLUjVpVWE1QmZldmlncnMybFJkSHhXVV9pdw?oc=5" target="_blank">Azacitidine/Venetoclax Combo Data Challenge Chemo in Fit Patients With AML</a>  <font color="#6f6f6f">AJMC</font>

Read Full StoryMore like this
"Induction chemotherapy fo" — Live Google News Trends & Headlines